Compass Therapeutics (NASDAQ:CMPX) Raised to Strong-Buy at Leerink Partnrs

Compass Therapeutics (NASDAQ:CMPX) was upgraded by Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other research firms also recently issued reports on CMPX. Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Jefferies Financial Group upped their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.63.

Compass Therapeutics Trading Down 24.6 %

Shares of CMPX stock opened at $1.69 on Tuesday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The firm’s 50 day moving average is $2.81 and its 200-day moving average is $2.11. The firm has a market capitalization of $233.70 million, a price-to-earnings ratio of -4.57 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, equities research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CMPX. Enavate Sciences GP LLC bought a new stake in Compass Therapeutics in the 4th quarter valued at $11,293,000. Tang Capital Management LLC boosted its position in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after buying an additional 4,087,005 shares during the period. MPM Bioimpact LLC grew its holdings in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC raised its position in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after buying an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Compass Therapeutics by 512.5% in the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after acquiring an additional 227,864 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.